Mese Pharmaceuticals, established in 1997, has been dedicated to providing innovative, high-quality pharmaceuticals and medical devices for nearly two decades. Initially, our company focused on research and development and the transfer of marketing authorization as our primary business, concentrating on the unmet market demand in the antibiotic field. The Amoxicillin Clavulanate Potassium tablets developed by our company were the first approved oral compound Amoxicillin preparations in China. We also invented Cefotaxime Sodium and Tazobactam Sodium for injection, creating a new pathway for the treatment of drug-resistant bacteria.

Since 2008, our company has established its own pharmaceutical sales company and obtained Good Supplying Practice (GSP) certification. Since then, our marketing authorizations are no longer transferred to others. Instead, we have adopted a contract manufacturing model for production and carried out the sales ourselves. Currently, our self-sold products mainly consist of exclusive gynecological drugs and patented gynecological devices. Leveraging our research and development advantages, we are actively planning for new products in the fields of anti-tumor, digestion, and anti-infection.

At present, our innovative traditional Chinese medicine for the treatment of non-small cell lung cancer has successfully completed Phase II clinical trials and has entered Phase III. Several digestive drugs in our pipeline are expected to be approved within the next two years.